Patrick Serruys
Latest contributions
Is there a rule for DCB in ACS setting?
22 May 2026 – From EuroPCR 2026
This session examines the application of drug-coated balloons (DCB) in the acute coronary syndrome (ACS) setting, comparing outcomes with drug-eluting stents (DES). It discusses the impact of intraluminal thrombus, real-world registry data on DCB-first strategies in STEMI, and multicentre experiences with DCB use in STEMI and...
Ascending into the future with drug-coated balloons
21 May 2026 – From EuroPCR 2026
Step into the future of interventional cardiology with comprehensive insights into drug‑coated balloons (DCB). This session covers the new DCB ARC guidelines, previews findings from the impactful BASKET BALL randomised trial, and examines real-world evidence from the SCORE registry. It also addresses the optimisation of acute...
TAVI sub-studies - Beyond the primary endpoint
21 May 2026 – From EuroPCR 2026
This session reviews key sub-studies from major TAVI trials that extend beyond primary endpoints to provide a deeper understanding of valve performance and patient outcomes. It covers comparisons between balloon-expandable and self-expanding valves, long-term real-world data on the Myval valve, echocardiographic outcomes, composite endpoint analyses, and...
Expanding the horizon - Trials addressing unchartered territories in coronary and structural heart
20 May 2026 – From EuroPCR 2026
New clinical evidence is pushing coronary and structural heart therapy into areas that were previously uncertain or inconsistently defined, with multiple landmark trials now shaping future practice.
Among the studies discussed in this EuroPCR 2026 session, are SORT OUT XII, START YOUNG, BISCUSPID, LANDMARK 2 and RESTORE...
TAVI: head-to-head trials
20 May 2026 – From EuroPCR 2026
This session presents head-to-head comparisons of TAVI devices from recent randomized trials and registries. Highlights include three-year outcomes from the SMART trial, two-year data from the LANDMARK trial on contemporary valves, comparisons of intra- and supra-annular self-expanding valves, evaluations in large annuli, the ALLEGRA trial focusing...
Back to the future - Lessons from the past that can guide contemporary practice
20 May 2026 – From EuroPCR 2026
Reflecting on historical perspectives in the management of atherosclerotic coronary vascular disease, this session imparts valuable lessons to guide contemporary PCI practice. It emphasizes best practices in vessel preparation, evaluates the significance of drug-eluting stents, and provides a pathologist’s insight into mechanisms of PCI failure to...
Align for the future with structural heart innovations - LIVE case and major trial updates
19 May 2026 – From EuroPCR 2026
Stay abreast of structural heart innovations with expert discussions on best-in-class transcatheter aortic valve implantation (TAVI) practices, including imaging, sizing, and procedural strategies. This session with LIVE case introduces the novel Myval Octapro+ transcatheter heart valve (THV), its design philosophy, and potential clinical benefits, along with...
Procedural planning and risk stratification in multivessel PCI
22 May 2025 – From EuroPCR 2025
This session focuses on procedural planning and risk stratification in multivessel PCI, presenting data from the TALENT and FIRE trials, prognostic value of post-PCI physiological assessments, and an innovative study comparing large language models in managing complex interventional cardiology cases.
The Landmark RCT - One-year results
21 May 2025 – From EuroPCR 2025
This session presents a detailed analysis of a landmark randomized controlled trial evaluating the Myval transcatheter aortic valve implantation (TAVI) system among other contemporary transcatheter valves. The discussion centers on one-year clinical outcomes, with a particular focus on women, patients with small aortic annuli, and those...
Hotline TAVI 1: extended analysis of the randomised trials
21 May 2025 – From EuroPCR 2025
Gain comprehensive insights from extended analyses of randomized TAVI trials. This session reviews five-year UK TAVI outcomes, cardiac damage evolution in asymptomatic aortic stenosis, one-year results from the LANDMARK trial, and three-year comparisons of balloon-expandable valves, highlighting critical clinical implications.
Supraflex for high-risk patients and lesions: from practice to evidence-based medicine proven through FIRE and COMPARE
20 May 2025 – From EuroPCR 2025
Discover the latest evidence on the Supraflex thin-strut sirolimus DES in complex cases—from small vessels and diabetes to STEMI—supported by OCT analysis. This session highlights Supraflex’s performance in high bleeding risk and elderly patients, featuring data from FIRE, COMPARE, EARTH HBR, and Cruz Senior studies. Get...
Align for the future with the Myval Octapro transcatheter heart valve series
20 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session offers a practical and evidence-based update on the Myval Octapro THV. Learn step-by-step techniques for valve-in-valve TAVI using the OctaAlign approach, and understand how intermediate sizes and precise deployment contribute to optimised hemodynamics and long-term durability.
Clinical insights are backed by key data...
